Index

A

Adenosine 5′-triphosphate (ATP), 274, 276, 278–280

Adherens junctions (AJs) in epithelial cells, 185–186, 428–429

Adhesion molecules, 7, 23, 26–27, 39, 59–60, 66–67, 70–72, 98, 107, 130–131, 159–160, 178, 201, 223–224, 231, 235–237, 242–243, 347, 368, 375, 377, 380, 428, 430–431

Agrin, 43, 50, 52–54, 57, 60–62, 68, 71, 96, 273–275, 352, 391, 407–410, 412, 415–416
- alternative splicing and activity, 400–401
- cholinergic transmission, antagonistic role of, 402–403
- in CNS
  - inter-neuronal synapse formation, 412
- in ECM, 400
- postsynaptic sites and, 401–402
- protein structure and synaptic association, 399
- signal transduction
  - MuSK activation, 401
- *in vitro* AChR clustering, 398–399

Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), 130, 171, 349, 358
- AMPA-receptors (AMPAR), 94, 98, 256, 274, 283, 390
  - and glutamate release, 310–311
- receptor-mediated EPSCs, 358
- type receptor, 390–391

Alternative splicing, 18, 147, 207, 210–211, 265, 269, 351, 353, 361, 399–400

AMIGO proteins and neurite outgrowth, 375

γ Aminobutyric acid (GABA), 87–88, 90, 125, 130, 279, 308, 318, 352, 359
- GABAergic synapses, 147, 251, 256, 328–329, 349, 353, 357–358, 360

Ankyrins adaptor proteins, 247, 258
- synaptic maintenance and functionality, 25

Anterior corner cell (aCC), Caps expression in, 15

Aplysia californica, ApCAM expression, 266

Arcadlin as cadherin-like molecule, 165, 177–178

Artificial synapse formation assays for neurexin–neuroligin splice code, 355–356

Asperger syndrome, 143, 145–146, 359–360
- *See also* Autism spectrum condition/disorder (ASC/ASD)

Attention-deficit hyperactivity disorder (ADHD), 145

Autism spectrum condition/disorder (ASC/ASD), 142, 347, 359
- Autism Genome Project Consortium, 146
- *CNTN*/*CNTNAP* pathway and, 149
- *CNTN3*/*CNTN4* as susceptibility gene for, 148
- *CTNAP2* mutations, 148
- neurexins, gene polymorphisms in, 359–361
- neuroligin genes, 143
  - polymorphisms in, 359–361
- *NLGN* point mutations/deletions, 143–145
- *NRXN1* alteration and, 145–146
- NRXN/NLGN for synaptic specificity, 147
- *SHANK3* genes, 145
- X-linked ichthyosis (XLI), 143–144

Axelrod, J., 4, 6
neurotransmitter degradation by enzymes and by surrounding cells, 6
Axons, 91, 114, 118, 166–167
axotomized $\beta_2m^-/^-$motoneurons, 309
CAMs and adhesion
axon–axon, 21
axon–ECM, 20–21
axon–muscle, 21
pruning in CNS, 131
in cerebellum, 118–121
in hippocampus, 107–109, 114–118
in visual system, 121–125
Axosomatic synapses, 431
See also Synapses

B

Basal lamina at vertebrate NMJ, 39, 43, 49, 57, 59, 65, 72, 94, 391, 398–399, 403, 405, 408, 411–412, 415
glyco-epitopes, 51–52
molecular composition, 50–51
role of, 50
See also Vertebrate neuromuscular junction (NMJ)
Bassoon and Piccolo, 89
See also Presynaptic scaffold molecules in CNS
Bernard, C., 40
studies on effects of paralytic neurotoxin, 40
Bidirectional signaling
neurexin–neuroligin trans-synaptic complex role in, 359
semaphorins and, 322–323
Borna disease virus
functional immune response and, 312
Bungarotoxin (BTX)
AChRs within postsynaptic membrane, labeling, 42, 45, 56
and neuromuscular synapse elimination, 111

C

Ca^{2+}/calmodulin-activated Ser-Thr kinase (CASK), Ca^{2+} and K^+ channels, 356–357
Cadherins and protocadherins (CDH/PCDH), 18, 94–95, 160–162
calcium-dependent cell–cell adhesion, 164
mutations and
EFMR, X-linked disorder, 151
Usher syndrome (USH), 150
role in
axon targeting, 166–167
dendrite and dendritic spine morphogenesis, 167–168
synapse formation and maturation, 168–170
synapse function and plasticity, 170–171
structures of neuronally expressed superfamily members, 164
in synapse remodeling, 199–200
Caenorhabditis elegans, 66, 209, 230, 235, 248, 266–267, 434
LAD-1 and LAD-2, 248
syg-1 and *syg-2* genes, 235
presynaptic terminals in HSN axons, localization of, 238
Capricious (Caps), 15
See also Cell adhesion molecules (CAMs)
CASK MAGuKs superfamily protein, 89–90, 189, 201, 243, 349, 356, 359–360
CASK gene mutations and FG syndrome, 360
See also Presynaptic scaffold molecules in CNS
Catenin, 161, 164
Cell adhesion molecules (CAMs), 7, 16, 20, 22, 32, 64, 91, 93, 108, 130, 141–143, 152–154, 201, 214, 224, 247, 249–254, 256–258, 273–275, 279, 373
aplysiaCAM (apCAM), 266, 269, 272, 277, 284–285
components of synaptic connections, 7
expression pattern at embryonic NMJ, 23–24
L1-type, 144, 247–258, 273–274, 373–375
mediated postsynaptic signaling hub, 29–31
mediate FORCES, 26–27
myopodia for navigating motor axons, 28–29
and neuromuscular network formation
postsynaptic cell pattern, 22–24
presynaptic cell pattern, 20–21
at NMJ
capricious (Caps), 15
connectin (Con), 15–16
Down syndrome cell adhesion molecule, 16

fasciclin II (FasII), 16–17
fasciclin III (FasIII), 17
integrins, 17–18
mediated intracellular signaling activation, 25–26
N-cadherin (N-Cad), 18
neuroglian (Nrg), 18–19
research work on, 31–33
Toll, LRR family of transmembrane proteins, 19
in NMJ plasticity, 27
polymorphisms and susceptibility, psychiatric conditions, 152–153
synaptogenesis
function of, 91
loss-of-function phenotypes in formation, 95–96
two-step model for CAM-mediated NMJ formation, 27
See also Vertebrate neuromuscular junction (NMJ)
Cell–cell junctions in neurons, 186, 195
Cell surface expression of MHC class I in neuronal subpopulations, 303
Central nervous system (CNS), 12–15, 19–21, 29, 71–72, 108, 123, 159–160, 166, 173, 200–201, 223–225, 243, 247, 253–254, 257, 259, 270–271, 275, 301, 303–305, 309–311, 329, 333, 348, 372, 378, 387, 390–392, 408–416, 430, 433
synapses, 414
formation of, 85, 92, 94
molecules at, 87–91
ultrastructure, 86–87
synaptogenesis in
axon with dendrite, contact and differentiation, 91–93
maturation and maintenance, 93–94
molecules, 94–99
Cerebellum, 2, 98, 108, 126, 148–150, 176, 201, 225, 253, 269–270, 311, 348, 414, 432
axon pruning in
CAMs role in, 121
cellular mechanism, 120–121
climbing fibers and Purkinje cells, contacts between, 118–119
redundant climbing fibers regression, 119
Necl-2, expression in, 201
Cheerio effect®, 428–429
See also Gap junctions as electrical synapses
Chicken, NCAM1 and NCAM2 expression, 266
Classical cadherins/catenins, 161–162
type I and II, 164
Collagen, 20, 49, 61–62, 67, 274, 398, 406–407, 413
collagen IV, 20–21, 49–50, 60, 63–70, 403
ColQ proteins and AChE interaction, 407
Connectin (Con), 15–16, 23
See also Cell adhesion molecules (CAMs)
Connexin (Cx) hemichannels, 8, 424–426, 430–432, 434–435
See also Gap junctions as electrical synapses
Connexin/pannexin-containing gap junctions, electrical synapses, 8
See also Gap junctions as electrical synapses
Contactin and contactin-associated proteins, 249, 274, 360
CNTNAP2 gene, autism susceptibility gene, 360
CNTN3 and CNTN4, alterations of, 148
members of, 147
mutations in, 152
Contact inhibition, nectins and Necl-5 function, 194
Cortical dysplasia-focal epilepsy syndrome (CDFE) and *CNTNAP2* mutations, 148
Couteaux, R., 41, 59
Cytomatrix at active zone (CAZ)-associated protein CAST, 89
Cytoskeleton, 7, 16, 25–26, 32, 55–56, 94, 147, 150, 164, 188, 190–193, 199–200, 209, 215, 243–244, 247–249, 277, 324, 327, 340, 385, 412
Cytotoxic T lymphocyte (CTL)
axonal lesions, 313
mediated immune response, 312

D

Dale, Sir H., 4, 5, 6, 40
chemical-centered signal transmission at synapse, view on, 6
Deiters, O. F. K., 1

Dendrite, 91–93, 114–115, 119–120, 159, 169, 197, 220, 224, 236, 339, 341, 356, 379, 390
spine, 166–168, 196, 309, 327, 329, 340, 392
de Robertis, E., 6
Neuron Doctrine, morphological proof of, 6
Doublecortin, 249, 254
mutations in neurological disorder, 250
Down syndrome cell adhesion molecule (Dscam), 16, 95, 154, 207–220, 223–224, 227–232
branch segregation and self-avoidance, 215–217
cytodomains of, 210
family members identification, 208–209
homophilic interactions, 213
function, 215
isoform-specific, 214
S-shape conformation, 214
Ig domains and fibronectin type III modules, 209
isoforms of, 215
mediated repulsion, 216
molecular diversity, 210–213
mRNA expression studies, 212
mutant neurons, 217
non-arthropod DSCAM transcripts, alternative splicing, 210–211
non-DSCAM interactions, 219–220
non-repulsive functions, 218–219
PDZ-binding motif, 231
structural domains of, 229
tiling, 217–218
See also Cell adhesion molecules (CAMs)
Drosophila melanogaster, 11–20, 22–28, 31, 33, 166–167, 171, 174, 176, 178, 209, 213, 216–218, 228–230, 232, 235–236, 240–241, 248, 254–256, 266–267, 269, 271, 276–278, 283, 285, 325, 388, 391, 410, 434
Dscam genes, 209, 211
transcript and protein structure, 212
Dscam-mediated homophilic repulsion, 215
embryonic development, 13
eye patterning, 241
flamingo mutants and motor axons, 175
IrreC and *Duf* genes, 236
Kekkon (Kekkon 1–5) protein and, 368
muscle nomenclature conversion, 14
myoblast fusion in, 240–241
nervous system, 12
neuromuscular junction (NMJ), 12
CAM-mediated intracellular signaling, 24–26
and CAMs, 15–19, 32
as model for studying regulatory mechanisms for mammalian central glutamatergic synapses, 13
sequence of events, 31
stereotypic embryonic neuromuscular cellular pattern, 22
neuromuscular network
as genetic and cell biological model, 12
representation of, 14
self-avoidance in, 215
Volado (Vol) gene, disruption of, 388
wild type and mutant *nrg,* ultrastructural comparison between, 255
Dye coupling, 434
Dystroglycan, 71, 349, 351–352, 400–401, 403–404, 412, 416
cell surface receptor at NMJ, 409–410
ECM organization and AChR clustering, 351–352

E

Eccles, Sir J., 4, 5–6, 118
EFMR, X-linked disorder, 151
See also Cadherins and protocadherins (CDH/PCDH)
Electrical coupling, 40
impulse activity, synchronization of, 431
Elliott, T. R., 5
mechanism and chemical nature of synaptic signals, 5
Eph family, 334–335
Eph receptor, 115–116, 224, 237, 333, 341
Eph receptor tyrosine kinases (RTKs), 333–334
axon pathfinding, 336
family members of, 334
protein domain organization of, 335
synapse formation in CNS, 338–341
Ephrins transmembrane proteins
axon pathfinding, 336
diverse projections in developing brain, role in, 115–116
EphA5 receptor, postnatal development, 116
overexpression of, 337
EphB, 98–99, 237
expression in CNS, 98–99, 115–116

GPI-anchored ephrins in, 336
hippocampal formation and, 116
neuromuscular topography and synapse formation in PNS, control, 336–337
protein domain organization of, 335
synapse formation in CNS, 338–341
Epilepsy and *CNTNAP2* alterations, 149
Excitatory synapses (type I synapses), 86–87
Extracellular matrix (ECM), 7, 72, 125, 193, 249, 265, 274, 352, 385, 391, 397, 416
aneural clusters and change, 54
brain of, 414
CNS synapses, molecules in
agrin in, 412
laminins in, 412–413
proteoglycans, 413–414
thrombospondins, 414–415
composition of, 398
and NMJ formation, 20
agrin, 398–403
collagens, 406
dystroglycan, 409–410
growth factors, importance of, 410–411
laminins, 403–406
matrix components, 406–407
proteases, 407–408
synapse-specific carbohydrates, 408–409

F

Fasciclin II (FasII), 16–17
Fasciclin III (FasIII), 17
Fat-like protocadherins single-pass transmembrane proteins, 175
Fibroblast growth factor (FGF)
FGF22 fibroblast growth factor family and presynaptic differentiation, 98
fibroblast growth factor receptor (FGFR), 249, 375
mediated signaling cascade, 272
Filopodia, 27–29, 31–33, 91–92, 193, 195–197, 216, 378, 428
Foster, Sir M., 3, 86, 303
Handbook of Human Physiology, 3
Fragile X mental retardation protein (FMRP)
fragile X syndrome, 361
role in normal synapse maturation and neuronal plasticity, 117
Fukuyama's muscular dystrophy, 352, 409

G

Gap junctions as electrical synapses, 423
clustering mechanism, 429
connexin in, 424–425
in development, 433–434
dye and electrical coupling, measurements of, 434
formation between neurons, specificity, 430
mixed synapses, 432–433
projection neurons, coupling of, 432
types of, 431
formation specificity in central nervous system, 430
mechanism for, 429
new channels, timed labeling of, 426
opening of, 427–428
multiple channels, dependence on, 428
pannexins/innexins, 434
functional differences, 435
as sites of attachment, 428–430
small central areas, internalization of, 427
See also Synapses
Gary, G., 86
Gray type I and Gray type II synapses, 86
synaptic contacts between neurons in CNS, evidence of, 86
Gephyrin scaffold protein, 90–91, 97, 253, 356
See also Postsynaptic scaffold molecules in CNS
Gilles de la Tourette syndrome and *CNTNAP2* alterations, 149
Glutamatergic synapses, 11, 13, 33, 89, 121, 146–147, 252, 256–257, 306, 308–312, 315, 328–329, 353, 358, 360, 433
Glycosylphosphatidyl inositol (GPI), 147–148, 169, 249, 265, 268–269, 271, 273, 279, 284, 322, 335–336, 407
GPI-anchored ephrins in cholesterol-rich microdomains in cell membrane, 336
GPI-anchored isoform of Xenopus NCAM2, 271
Glycosyltransferase genes and human diseases, 409
Golgi, C., 1, 2, 3, 4, 5, 8, 414
histological staining procedure, 2
Nobel Prize for physiology/medicine, 3
Reticular Theory, 1
Growth cone, 16, 21, 28–29, 32, 52, 55, 59, 91, 96, 322, 324–325, 336, 367, 379–380

H
Hebbs, D., 112, 126, 129
Heparan sulfate proteoglycan (HSPGs), 403, 407, 414
  agrin, 399
  BL of vertebrate NMJs, 49, 60, 63, 67
  and fibroblast growth factors (FGFs), 410–411
  NCAM and, 377
Heterodimeric (αß) transmembrane receptors, 385
Hippocampus, 92, 114, 116–117, 120, 126, 169–170, 195–198, 200, 225, 251–253, 269–270, 275, 278, 281–283, 286, 304, 306, 310–312, 315, 326–327, 338–340, 348, 355, 387, 392
  CA1 and CA3 cells in neurexin gene expression, 351
  and cerebellar axon pruning, 115
His, W., 1, 2, 3, 4
  dendrites term for cytoplasmic neuronal processes, 3

I
Immunoglobulin (Ig) superfamily proteins, 17, 94, 97, 147, 166, 208, 223, 229, 247, 273, 387
  Ig domain, 187, 190, 207, 209–214, 244
Inner plexiform layer (IPL), 19–20, 25–29
Innexins, 424, 434–435
Integrins, 17–18, 385
  at CNS synapses
    dendritic spines, 390–391
    and memory, 388–389
    neurotransmitter receptors and, 389–390
    pharmacological and genetic manipulations, 388
    synaptic plasticity, 387–388
  heterodimer, representation of, 386
  in NMJ synapses, 391
    functions for, 392
  synaptic neuropathology, role of, 392
  See also Cell adhesion molecules (CAMs)
Invertebrate semaphorins and synapse development
  giant fiber motor neuron (GF-TTMn) synapse, 325–326
  Sema-1a, role of, 325–326
IrreC/Nephrin/SYG-1 family of adhesion molecules, 235
  L1-syndrome, 250
  phylogenetic analysis of, 236
  SYG-1 and *SYG-2* as synaptic target of HSNL neuron in *C. elegans,* 235–240

K
Katz, Sir B., 4, 6, 41
  neurotransmitter molecules from presynaptic termini and, 6
Killer cells
  killer cell activating receptor-associated protein (KARAP), 311–312
  killer cell immunoglobulin-like receptors (KIR), binding partners for MHC class I molecules, 311
Kühne, W., 40
  studies on NMJs as sites of neurotransmission, 40

L
Laminins, 39, 62, 71, 403–405, 412–413
  in CNS, 412–413
  composition of, 403
  functions of, 405
  pre and postsynaptic specializations, 405–406
  specificity, 224–230
  structure and synaptic association, 404
Langley, J. N., 5
  mechanism and chemical nature of synaptic signals, 5
Lateral geniculate nucleus (LGN), cellular and subcellular expression of MHC class I in, 306
α-Latrotoxin (α-LTX) and neurexins search, 347–348
Leech, LeechCAM expression, 266
L1 syndrome, 143, 250
Leucine rich repeat (LRR), 19, 367–369, 373, 375–376
Leucocyte immunoglobulin-like receptor (LILR) and Ly49, MHC class I antibodies, 306
Lissencephaly gene-1 *(LIS-1)* mutations in neurological disorder, 250
Loewi, O., 4, 5, 40
  signaling across synapses, experiments on, 5
Long-term potentiation (LTP), 387–388

L1-type cell adhesion molecules (L1-CAM), 144, 247–258, 253, 273–274, 373–375
FIGQY-motif in, 254
L1-syndrome, 253
structure, 247
synaptic functions
learning and memory, 250–252
in synaptogenesis, 253–256
targeting, 252–253
transmission and signaling, 257
Lymphocytic choriomengingitis virus (LCMV)
functional immune response and, 312
Ly-49 receptor, inhibitory and activating effects in immune system, 311

M

McMahan, U. J., 59–61, 398
The Agrin Hypothesis, 398
Major histocompatibility complex class I (MHC class I), 123
assembled in ER by transporter associated with antigen processing (TAP), 302
deficiency of, 306–308
dependent immune-mediated cytotoxicity, 303
dependent synapses in nervous system and immune system, 309
expression and regulation, *in vitro* and *in vivo* studies, 303
tetradotoxin (TTX) and IFN-γ treatment, 304
function of, 302
neurological diseases and, 314–315
nonsynaptic functions
neuronal susceptibility and immune-mediated cytotoxicity, 312–313
vomeronasal organ, 313–314
signaling, 309
structure, 301
synaptic functions
in axotomized spinal cord, synaptic elimination, 307–309
expression in neurons, 302–303
putative neuronal class I receptors, 310–312
surface expression, 305–306
synaptic plasticity in developing and adult brain, 306–307
Manduca sexta, transmembrane fasciclin II form by neuronal cells in CNS, 269
Membrane-associated guanylate kinase (MAGUK) proteins, 188, 256, 356, 367, 372
in assembly and organization of cell junctions, 89–90
See also Synaptic adhesion-like molecules (SALMs)
Mental retardation, 117, 141, 145, 149–151, 153, 176, 199, 208, 250, 347, 352, 392, 408–409, 416
neurexins and neuroligins, gene polymorphisms in, 359–361
ß$_2$-Microglobulin (ß$_2$m) polypeptide, 301
See also Major histocompatibility complex class I (MHC class I)
Miniature postsynaptic currents (mPSCs), 358
Mint1 cytoplasmic proteins CASK-interacting proteins, 89
Mossy fibers (MB), 114, 117, 197–198, 351
and infrapyramidal bundle (IPB), synaptic complexes, 115
Motor axons, 11, 15, 20–21, 28, 42, 44, 48–49, 52, 54–56, 59–60, 62, 65, 111–112, 175, 337, 402, 411
innervation
multiple muscle fibers within same muscle, 45
muscle by, 45
muscle-specific kinase (MuSK), role of, 53
P/Q type calcium channels and, 47
synaptic vesicle-associated proteins and, 46
Motor neurons, 12, 16, 52, 55, 60–62, 69, 110, 237, 269, 284, 336–337, 391, 400, 402–403, 405, 410–412
in developing CNS and muscle cell targets, 13
and presynaptic terminals, 44–47
Mouse hepatitis virus
functional immune response and, 312
Munc13-1, 88
See also Presynaptic scaffold molecules in CNS
Muscle–eye–brain disease (MEB), 352
Muscle-specific kinase (MuSK) as putative postsynaptic co-receptor,43, 50, 53–54, 67, 70–71, 274–275, 400–403, 407, 409, 412, 415
as putative postsynaptic co-receptor, 53–54, 275, 401
Myopodia filopodia like structures, 31–33
CAMs and motor axons, 28–29
and synaptogenesis, 19, 28

N
Narp overexpression and clustering of AMPA receptors at synapses, 98
Nasu-Hakola disease, lack of MHC class I receptors, 315
N-Cadherin (N-Cad), 18, 23, 95, 160, 166, 195–196, 199, 375, 379
See also Cell adhesion molecules (CAMs)
Nectin and nectin-like molecules (Necls), 95, 97–98
AJs and TJs, formation of, 192
axons and dendrites, selective association between, 199
cadherins and AJs, 190
CAMs and growthfactor receptor, interactions, 193–194
cell–cell adhesion activity, 189–190
cell–cell junctions in central and peripheral nervous systems, 200–201
genetic deletion effect on brain, 197
induced signaling, 192
molecular structures and, 188
nectin–afadin and cadherin–catenin system, association of, 191
properties of, 187
in synapse remodeling, 199–200
synapses formation and, 194–199
Nephrin in kidney development, 235–236, 241–243
Neural cell adhesion molecule 1 (NCAM1), 71, 224
ectodomains of, 269–270
extracellular ATP effect on function, 278–280
extracellular interaction partners of, 272
agrin, 275
chondroitin sulfate proteoglycans (CSPGs), 274
growth factors and growth factor receptors, 275–276
heparan sulphate proteoglycans (HSPGs), 274
Ig1–Ig2 and Ig1–Ig2–Ig3, 273
muscle-specific kinase (MuSK), 275
neurocan and phosphacan, 275
nicotinic acetylcholine receptors (nAChRs), 275
p75 neurotrophin receptor (p75NTR), 275
Prion protein (PrP^c), 273
TAG-1 and L1-CAM, 273
family members, 266
function
extracellular ATP effect on, 278–280
long-term potentiation and long-term depression, 283–286
polysialic acid regulatory roles on, 280–283
intracellular interaction partners
α-actinin 1, 277
ATP, 279
α-and ß-tubulin, 277
cytoskeleton, 277
cytosolic, 276
leucine-rich acidic nuclear protein (LANP/PHAP-1), 277
phospholipase Cγ (PLCγ), 277
serine/threonine phosphatases PP1 and PP2A, 277
spectrin, 277
syndapin, 277
voltage-dependent Ca^{2+} channels (VDCC), 277
mediated intracellular signaling pathways, 278
organization of, 268
phosphorylation and NF-κß transcription factor activation, 272
phylogenetic tree, 267
posttranslational modifications, 271–272
structure, 268–271
Walker A motif, 280
Neurexins, 89, 97, 121, 142–147, 152, 237, 306, 377
in brain, distribution of, 350
cell adhesion and synaptic plasticity, link between, 358–359
dystroglycan and neurexophilin, 351–352
gene polymorphisms in ASD and mental retardation, 359–361
genes, expression pattern of, 348
olfactory bulb, 351
intracellular signaling of, 356–357
longer α and shorter ß isoform, 348
ß -neurexins CASK-interacting proteins, 89
and neuroligins function in synaptogenesis, 97
splice sites of, 348
splicing of, 353
neuroligin 1 and neuroligin 3, 354–355
surface plasmon resonance (SPR) experiments, 354
structure of, 349
in vitro synapse formation assays, 355–356

Neurexophilin, 351–352
Neurite outgrowth, 149, 253, 270, 272, 274–280, 368, 372, 375, 377–378
  characteristics, 376
  PDZ domain proteins, 379
Neuroadapted Sindbis virus
  functional immune response and, 312
Neurofascin, 95, 247, 250, 252–254, 256
Neuroglian (Nrg), 18–19, 23, 248–249, 254, 256
  See also Cell adhesion molecules (CAMs)
Neuroligins, 93, 96–97, 121, 142–143, 145–146, 152, 169, 189, 196, 223, 237, 306, 349, 351, 373–375, 377–378
  cell adhesion and synaptic plasticity, link between, 358–359
  genes
    polymorphisms in ASD and mental retardation, 359–361
    and proteins structure, 352–353
  intracellular signaling of, 356–357
  and neurexins, 142–147
  PSD-95-Dlg-ZO homology (PDZ)-binding motif, 357
  splicing of, 353
    neuroligin 1 and neuroligin 3, 354–355
    surface plasmon resonance (SPR) experiments, 354
  structure of, 349
  in vitro synapse formation assays, 355–356
Neuromuscular junction (NMJ), 23, 32, 39
  chemical neurotransmission, 40
  development of
    AChRs clustering in absence nerves and nerve-derived cues, 53
    aneural AChRs and motor axons, 54–57
    muscle-specific kinase (MuSK), 53
    postnatal pruning of supernumerary nerve terminals, 57
    synaptic differentiation, 52
    synaptic maturation and maintenance, 57–59
  fluorescently labeled conjugated bungarotoxin (BTX), 42
  molecular signals and synapse formation, 41
  morphology of, 42–43
    motor neurons and presynaptic terminals, 44–47
    non-myelinating perisynaptic Schwann cells, 48–49
    postsynaptic apparatus, 47–48
    synaptic cleft and basal lamina, 49–52
  motor axons and nerve terminals, 42
  quantal and vesicular theories of neurotransmission, 41
  study of, 39
  synapses, molecular components of, 40
  synaptic partners and, 40
  and trans-synaptic cues, 59
    agrin, 60–61
    collagen IV, 63–65
    growth factors, 68–69
    laminins, 61–63
    matrix-degrading enzymes, 67
    matrix molecules, 66–67
    nidogens, 66
    synaptogenic molecules within synaptic BL, 60
    transmembrane adhesion molecules, 70–71
Neurons, 195, 236
Neuropilin, 323
Nidogen, 66
NK-cell receptors for MHC class I molecules, 302
N-Methyl-D-asparate (NMDA)-type receptor, 94, 99, 170, 189, 252, 256, 277, 281, 339–340, 390
  NMDA receptor-mediated excitatory postsynaptic currents (EPSCs), 358
Nobel Prizes for physiology/medicine for neuroscience discoveries, 4
NRXN–NLGN–SHANK pathway at synapses in human brain, 146

P

Paired immunoglobulin receptor B (PIR-B) and MHC class I antibodies, 306
Pannexins, 8, 424, 434
  pannexin/innexin junctions, 435
3p Deletion syndrome, 148
PDZ protein, 25, 228, 231, 235, 372
Pecot-Dechavassine, M., 41
Perineuronal nets (PNNs), neuron's synaptic connections, 414
Peripheral nervous system (PNS), 12, 19, 108–114, 200–201, 333, 392

Phosphatidylinositol-specific phospholipase C (PI-PLC) and cleavage of NCAM1, 279
Plexin A
activation and downstream signaling molecules regulation, 324
plexin-A3 mutants, 116
Polyneuronal innervation, 68, 110
Polysialic acid (PSA), 271
AMPA receptor-mediated currents and, 283
anti-adhesive property of, 282
axonal growth and, 282
FnIII1 module, 283
learning and memory formation, modulator of, 282
NCAM1-associtated expression, 281
and NCAM1 glycosylation, 280
nitric oxide (NO)-cGMP-mediated signaling, 281
ST8SiaII expression, 281
synthesis of, 280–281
Postsynaptic densities (PSDs), 86
Postsynaptic scaffold molecules in CNS
gephyrin, 90–91
ProSAP/Shank family proteins, 90–91
PSD95/SAP90 family, 90
Presynaptic scaffold molecules in CNS
Bassoon and Piccolo, 89
CASK, 89–90
Munc13-1, 88
RIM1, 88
Proteoglycans, 49–50, 60, 63, 66–67, 273–274, 377, 398, 403, 407, 410
Protocadherins (Pcdhs), 95, 150–151, 160, 163, 171
clustered, 172–174
in CNS extracellular matrix, 413–414
δ-Pcdhs, 176–177
Fat-type and 7-transmembrane, 174–176
murine Pcdh-α, Pcdh-ß and Pcdh-γ gene clusters, 165
See also Cadherins and protocadherins (CDH/PCDH)
PSD-95 family of MAGUK proteins, 25, 48, 90, 195–196, 304, 327–328, 335, 349, 356–359, 372
dendritic branching, 380
See also Synaptic adhesion-like molecules (SALMs)
Puncta adherentia junctions (PAJs), 186
Purkinje cells
and climbing fibers for study of synapse elimination, 118–119
early postnatal life, 115
stochastic pruning in developing cerebellum, 119–120
synaptic responses and, 120

Q
Quantal release hypothesis, 41

R
Rab3 acceptor protein PRA1, 89
Rabies virus
functional immune response and, 312
Ramon y Cajal, S., 1–5, 8, 59, 118, 225–226, 414
Neuron Doctrine of nervous system, 3
Nobel Prize for physiology/medicine, 3
Purkinje and granule cells drawings, 2
Reticular Theory, 1
Rasmussen encephalitis, 303
See also Major histocompatibility complex class I (MHC class I)
Rb-8-neural cell adhesion molecule (RNCAM), 266
Reelin ECM protein, 113
See also Synapses
Remak, R., 1
Retina
activity and BDNF, 124
Cad7 and Cad11, role in, 167
Ig superfamily molecules and laminar specificity, 227
MHC class I proteins and, 123
in multiple sublaminae, 225
photoreceptor ribbon synapse formation, 89
retinal ganglion cells (RGCs), axonal terminals and, 123
Sdk1 expression, 230
synaptic zones of, 174
Rett's syndrome (RTT), 145, 314
RIM1 molecules, 88
See also Presynaptic scaffold molecules in CNS
Robertson, J. D., 6, 41
Neuron Doctrine, morphological proof of, 6
Ruska, E. A., 6
first electron microscope, development of, 6

S
Schizophrenia and *CNTNAP2* alterations, 149
Schwann, T., 1
Semaphorin family, 21, 321–322
  discovery and organization, 322–323
  neuropilin and plexin receptors, 116
  non-plexin-dependent effects of, 324
  proteins, 323–324
  pruning of IPB in hippocampus, 116
  receptors, biological functions of, 324–325
  semaphorin/plexin complex, 325
  structures of, 323
  in synapse formation and function
    class 4 semaphorins, 328–329
    class 3 semaphorins (Sema3A), role of, 326–328
Shank 3 gene in ASD, 145, 360
Sherrington, Sir C. S., 3, 4, 86
Sidekick proteins (Sdks)
  laminar organization of retina, 225–226
  laminar specificity
    DSCAMs and, 228–229
    role in, 224
  molecular and cellular properties
    ectodomains and homophilic adhesion, 230–231
    intracellular signaling, 231
    structure and expression, 229–230
  PDZ-binding motif, 231
  structural domains of, 229
Silent synapses, 358
  See also Synapses
Sjöstrand, F. S., 6
  Neuron Doctrine, morphological proof of, 6
Synapses
  developmental stages during maturation of, 198
  elimination
    AChR territory and, 111
    activity-based competition process, 112
    asynchronous firing of motor axons, 112
    climbing fibers and Purkinje cells, 118–119
    in developing neuromuscular junction, 110
    in peripheral nervous system, 109
    p75 neurotrophin receptor (p75NTR)-mediated axonal degeneration and, 113–114
    postsynaptic ACh receptors (AChRs) and calcium influx, role in, 112–113
    reelin, role of, 113
  formation, 377–378
    PDZ domain proteins, 379
  history, 1
  intercellular junctions between axons and dendrites of neurons, 195
  stabilization, neurexins and neuroligins, role in, 356–360
  synaptic clefts, 86
    at vertebrate NMJ, 49
  and synaptic delays, 431
  synaptic junctions (SJs) sites of neurotransmission, 185–186
  synaptic vesicle (SV), 86
  synaptogenesis and
    in CNS, 91–94
    in HSN axons, 238–239
    muscle 12 expressing membrane-targeted GFP and RP5 motor axon, 30
    SynCAM1 protein expression and, 201
  types of, 431
Synaptic adhesion-like molecules (SALMs), 367
  associated proteins and functional significance, 372
  dual functions for, 378
    N-cadherin mediates, 379
    PSD-95 dendritic branching, 380
  family sequence comparison, 369
  homomeric and heteromeric interactions, 373–375
  multimerization and *cis*/*trans*-synaptic interactions, hypothetical model of, 374
  neurite outgrowth, 375, 378
    characteristics, 376
    glycosylation, 377
    PDZ domain proteins, 379
  phylogenic analysis, 368
  protein domain structure, 368
  species comparison, 371–372
  synapse formation, 377–378
  Western blot and subcellular fractionation experiments, 370
Synaptic plasticity, 387–388
  activity-dependent, 126
  CAMs role in, 130
  Hebb's rule, 126
  homeostatic synaptic plasticity, 128–129
  long-term potentiation (LTP) and long-term depression (LTD), 126–127
    presynaptic and postsynaptic, 128
  morphologic changes in, 200

Synaptic plasticity (*cont.*)
neural activity, role in, 126
NRXN/NLGN role in, 147
physiological and molecular mechanisms, 129
postsynaptic receptors, phosphorylation of, 127
Synaptic scaffolding molecule (S-SCAM) and neuroligins binding, 357
Synaptogenesis, 16–19, 21, 25–33, 41, 60, 68, 70, 72, 85, 115, 142, 174, 281, 355–356, 412, 414–416
agrin and, 275, 398–399
axons and dendrites, association between, 187, 199, 201
and cadherins, 166–167
CAM and, 236
in CNS, 91–94
FasII expression and FasII-mediated cell adhesion/signaling during, 285
in HSN axons, 238–239
L1-type cell adhesion molecules in, 253–256
MHC class I genes, 314–315
muscle 12 expressing membrane-targeted GFP and RP5 motor axon, 30
in PNS *in vivo*, 337–340
SynCAM1 protein expression and, 201
WNT7a and, 96–97
Synaptopathies
brain wiring alterations caused by CAM mutations in, 152
cell adhesion molecules (CAMs) in, 141
brain wiring alterations by mutations in, 152
phylogeny of, 144
structure, 143
SynCAMs immunoglobulin-superfamily and synapse formation, 97–98, 154, 169, 189, 201, 237, 377
Synchronization, 433
Syndecan 2 CASK-interacting proteins, 89, 130

T

Taiwanese banded krait venom α-bungarotoxin for study of vertebrate NMJ, 42
Tello, J. F., 59
Tetrodotoxin (TTX), 123, 129
and neuromuscular synapse elimination, 111
Thalamo-amygdala synapses of principal neurons, NMDA/ AMPA ratio, 358
Theiler's mouse encephalitis virus (TMEV) functional immune response and, 312
Thrombospondins, 96
at NMJ, 414–415
role in synapse formation, 99
Thymus-derived cytotoxic T-lymphocyte (CTL) surveillance, 302
See also Major histocompatibility complex class I (MHC class I)
Toll, LRR family of transmembrane proteins, 19, 23, 30
See also Cell adhesion molecules (CAMs)
Torpedo electric organ and NMJ isolation, 42–43
See also Vertebrate neuromuscular junction (NMJ)
Triggering receptor expressed on myeloid cells (TREM2), 311–312
Tubocurarine and neuromuscular synapse elimination, 111
Tumour necrosis factor alpha converting enzyme (TACE) and cleavage of NCAM1, 279
Type II inhibitory synapses, 87

U

Usher syndrome (USH), 150, 154, 178
See also Cadherins and protocadherins (CDH/PCDH)

V

van Gehuchten, A., 2, 3
VASE-containing NCAM1 proteins, 270
Veli/Lin-7 cytoplasmic proteins CASK-interacting proteins, 89
Verrall, W. A., 3
synapse term, 3
Vertebrate nervous system, 12
Vertebrate neuromuscular junction (NMJ)
chemical neurotransmission, 40
development of
AChRs clustering in absence nerves and nerve-derived cues, 53
aneural AChRs and motor axons, 54–57
muscle-specific kinase (MuSK), 53
postnatal pruning of supernumerary nerve terminals, 57
synaptic differentiation, 52

synaptic maturation and maintenance, 57–59
fluorescently labeled conjugated bungarotoxin (BTX), 42
molecular signals and synapse formation, 41
morphology of, 42–43
motor neurons and presynaptic terminals, 44–47
non-myelinating perisynaptic Schwann cells, 48–49
postsynaptic apparatus, 47–48
synaptic cleft and basal lamina, 49–52
motor axons and nerve terminals, 42
quantal and vesicular theories of neurotransmission, 41
study of, 39
synapses, molecular components of, 40
synaptic partners and, 40
and trans-synaptic cues, 59
agrin, 60–61
collagen IV, 63–65
growth factors, 68–69
laminins, 61–63
matrix-degrading enzymes, 67
matrix molecules, 66–67
nidogens, 66
synaptogenic molecules within synaptic BL, 60
transmembrane adhesion molecules, 70–71
Vesicles at excitatory presynaptic terminal
vesicular GABA transporter (VGAT), 87
vesicular glutamate transporter (VGLUT), 87
Visual system, axon pruning in, 121
astrocytes and C1q, role in, 123
CadN mutations and, 167
dorsal lateral geniculate nucleus (dLGN), 123
ECM role, 125
EphA receptor tyrosine kinases and ligands, 123–124
lateral geniculate nucleus (LGN), 122
in mammalian visual system, 122
MHC class I proteins, 123
neurotrophins role in ocular dominance column formation and plasticity, 124–125
retinal ganglion cells (RGCs) activities, 123
tissue-type plasminogen activator (tPA), 125
visual-driven activity and cortical connections, 124
Voltage-gated Ca^{2+} channels CASK-interacting proteins, 89
Vomeronasal sensory neurons (VSNs), 313
von Euler, U. S., 4, 6
noradrenalin as neurotransmitter of sympathetic nervous system, demonstration, 6
von Gerlach, J., 1
cellular organization of nervous system theory, 1
Reticular Theory, 1
von Kölliker, R. A., 2, 3
axon term for fiber-like extension, 3
von Waldeyer-Hartz, H. W. G., 2, 3
neuron term introduction, 3

W

Walker–Warburg syndromes, 352, 409
WNT proteins function in synapse formation, 96–97
Wnt7a, 97

X

X-Linked ichthyosis (XLI), 143–144

Z

Zebrafish, zNCAM/NCAM1-3 expression, 52, 54, 169, 240, 266–267, 270–271, 275, 280–281, 328, 402